You are here
The Progress Report Keep up-to-date with our community. From science coverage to fundraiser spotlights, get the latest news here.
NEW YORK, NY – December 11, 2019 – The Breast Cancer Research Foundation (BCRF) announced $5 million in funding provided by Eli Lilly and Company to conduct investigator-initiated studies of the CDK4 & 6 inhibitor, Verzenio® (abemaciclib).
An upcoming clinical trial will evaluate the use of contrast enhanced mammography as a breast cancer screening option for women with dense breast tissue
Raise money for lifesaving research this holiday season and throughout the new year.
Recorded Live from New York City
BCRF attended the fifth annual Conquer Cancer Scientific and Career Development Retreat designed to empower early career researchers.
Learn how you can become a Team BCRF runner in this year’s 13.1-mile race
Carol Chaoui who is living with metastatic breast cancer, will participate in the race with her daughter, Lina.
The inspiration of a BCRF metastasis researcher, recaps from signature events, ASCO 2019 science updates and more
BCRF Corporate Partners offer simple ways to give back this month and beyond.
The Editor-in-Chief of ELLE magazine will host BCRF's upcoming Symposium & Awards Luncheon
Explore
Categories
Editor's Picks
Stay Up To Date
Don’t miss out. Let us update you when we post stories you care about.